← Back to patent-cliff list
JAB-2485
Tier C — Watch / tradeJAB-2485
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AURKA
Indications (approved)：Breast cancer, 三阴性乳腺癌, Solid tumour, Small cell lung cancer
Regional status
US
Phase II
2022-12-20
EU
-
China
Phase II
2022-12-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JAB-2485?
Approved indications include: Breast cancer, 三阴性乳腺癌, Solid tumour, Small cell lung cancer.
When does the JAB-2485 patent expire?
No public expiry year is available for JAB-2485 yet; this page updates once verified.
How do I get a quote for JAB-2485 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03